ISUPREL
LOE ApproachingNDARECTAL, SUBLINGUALTABLET
Approved
Feb 1948
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ISUPREL is a small-molecule sympathomimetic amine approved in 1948 for rectal and sublingual administration as a tablet formulation. The drug's specific mechanism of action and approved indications are not documented in available data, limiting clinical characterization. This historic product represents a legacy therapeutic from the mid-20th century pharmaceutical era.
LOE Approaching
Product approaching loss of exclusivity with minimal competitive pressure (30% rating) and zero linked job openings, indicating a wind-down commercial organization.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ISUPREL currently has zero linked job openings, reflecting a mature product with minimal organizational investment and commercial infrastructure. Career opportunities on this asset are severely constrained, making it an unattractive placement for growth-oriented professionals.
Brand ManagerField Sales
Worked on ISUPREL at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.